Katalin Karikó

Katalin Karikó was born on January 17, 1955, in Kisújszállás, a small town on Hungary's Great Plain. Her father was a butcher; her mother worked as a bookkeeper. The family lived without a refrigerator, television, or running water until Karikó was a teenager. She credits her early fascination with biology to long walks in the countryside and an excellent high school teacher who encouraged her scientific curiosity. Hungary's centralized education system gave her access to university despite her rural background.

Karikó attended the University of Szeged, earning her PhD in biochemistry in 1982 under the supervision of Professor Jenő Tomasz. Her doctoral research focused on RNA modification and antiviral mechanisms—early work that planted the seeds of her lifelong pursuit. After graduation, she took a postdoctoral position at the Hungarian Academy of Sciences' Biological Research Center in Szeged. When her lab lost funding in 1985, she made a life-changing decision: she and her husband sold their car on the black market, hid £900 (roughly $1,200) in their toddler daughter's teddy bear, and moved to the United States to continue her research.

Karikó arrived in the United States in 1985 and took a postdoctoral position at Temple University in Philadelphia, then moved to the University of Health Sciences in Bethesda, Maryland. In 1989, she joined the University of Pennsylvania, believing its resources and research culture would support her growing conviction that synthetic mRNA could be used as a therapy. The idea was straightforward: if you could deliver mRNA into cells, those cells would produce therapeutic proteins on demand—turning the body into its own drug factory. The obstacle was equally straightforward: the immune system recognized foreign mRNA as a viral invader and triggered a dangerous inflammatory response.

Through the 1990s, Karikó struggled. Grants were rejected. Her colleagues moved toward more fashionable fields like gene therapy using DNA or small interfering RNA. In 1995, the University of Pennsylvania demoted her from a tenure-track position to a non-tenure research role—a professional setback that reduced her status and pay. She was told repeatedly that mRNA research was a dead end. Despite the isolation, Karikó kept working, convinced the problem was solvable.

The breakthrough came in the early 2000s after a chance meeting at a photocopier. Drew Weissman, an immunologist who had trained under Anthony Fauci at the NIH, was also at Penn, working on vaccine development. Karikó and Weissman began collaborating in 1997. By 2005, they published a landmark paper in the journal *Immunity* demonstrating that replacing one of mRNA's four nucleosides—uridine—with pseudouridine dramatically reduced the immune system's inflammatory response. This nucleoside modification allowed synthetic mRNA to slip past immune defenses and deliver its payload quietly. It was the key that unlocked therapeutic mRNA.

The 2005 paper attracted little attention at the time. Karikó and Weissman patented their discovery through Penn, but pharmaceutical interest was minimal. Karikó continued refining mRNA delivery and stability. In 2013, frustrated by continued lack of institutional support at Penn, she left to become a senior vice president at BioNTech, a small German biotech company founded by Uğur Şahin and Özlem Türeci. BioNTech was one of the few firms betting on mRNA therapeutics. Karikó remained an adjunct professor at Penn while working in Germany.

Karikó's singular achievement is demonstrating that synthetic mRNA can be chemically modified to evade immune detection while retaining its protein-coding function. This discovery directly enabled the mRNA vaccine platform used by Pfizer-BioNTech and Moderna during the COVID-19 pandemic. When SARS-CoV-2's genetic sequence was published in January 2020, BioNTech—with Karikó as a key scientific leader—used her nucleoside-modified mRNA method to design a vaccine in a matter of days. Clinical trials followed with extraordinary speed, and in December 2020, the Pfizer-BioNTech vaccine became the first mRNA vaccine authorized for emergency use. Moderna's mRNA vaccine, also built on Karikó and Weissman's foundational work, followed days later.

The impact was staggering. By mid-2023, more than 13 billion doses of COVID-19 vaccines had been administered worldwide, the vast majority using mRNA technology. Studies estimate these vaccines prevented millions of deaths and tens of millions of hospitalizations. Beyond COVID-19, Karikó's work has opened a new chapter in medicine. MRNA is now being explored to treat cancer, genetic diseases, infectious diseases like influenza and HIV, and autoimmune conditions. What was once dismissed as too unstable and inflammatory is now a versatile, programmable platform.

Karikó's persistence through decades of rejection also reshaped conversations about how science is funded and recognized. Her career illustrates the dangers of short-term thinking in research: transformative ideas often require patient, unglamorous work that doesn't fit neatly into grant cycles or institutional priorities.

For most of her career, Karikó received little recognition. That changed abruptly with the pandemic. In 2020 and 2021, she and Weissman were inundated with awards. They received the Lasker-DeBakey Clinical Medical Research Award in 2021, often considered a predictor of the Nobel Prize. The same year, they were awarded the Breakthrough Prize in Life Sciences. Spain's Princess of Asturias Award for Technical and Scientific Research followed. In 2022, Karikó and Weissman received the prestigious Vilcek Prize and were named to Time magazine's list of the 100 most influential people.

The culmination came on October 2, 2023, when the Nobel Assembly at the Karolinska Institute awarded Karikó and Weissman the Nobel Prize in Physiology or Medicine 'for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.' The Nobel Committee noted that the laureates' findings were critical for developing vaccines at unprecedented speed during the pandemic. Karikó became the 13th woman to win the Nobel Prize in Physiology or Medicine and the first Hungarian woman to receive a Nobel in science.

Karikó has also been honored by her native Hungary. The University of Szeged, her alma mater, awarded her an honorary doctorate. The Hungarian government, which had provided no support during her decades of research, celebrated her achievements publicly. These honors arrived decades after the work was done—a reminder that transformative science often gestates in obscurity.

Katalin Karikó's legacy operates on two levels. Scientifically, she is the mother of therapeutic mRNA. Her dogged investigation of nucleoside modification created a technology that will define 21st-century medicine. The COVID-19 vaccines are the first chapter; mRNA-based treatments for cancer, rare genetic disorders, and chronic infections are in development. Companies like BioNTech, Moderna, and CureVac are building entire pipelines around the platform she pioneered. Academic labs worldwide are exploring mRNA for applications Karikó once only imagined.

Personally, Karikó's story has become a parable about resilience and the long arc of scientific discovery. She worked for decades without major funding, institutional prestige, or peer recognition. She was demoted, overlooked, and advised to quit. She kept working. Her vindication—when it came—was total, but it required an almost unreasonable faith in her idea. That faith, combined with rigorous biochemistry and a crucial collaboration with Weissman, changed history.

Karikó retired from BioNTech in 2022 but remains active in research and advocacy. She speaks frequently about the need to support basic science, especially work that doesn't promise immediate payoffs. She is a fierce advocate for women in STEM and for recognizing the contributions of immigrant scientists. Her daughter, Susan Francia, is a two-time Olympic gold medalist in rowing—a detail Karikó mentions with evident pride, a reminder that even as she pursued mRNA in the lab, she built a full life beyond it. In interviews, she is generous, self-deprecating, and stubborn. She remains, in her own words, 'just a scientist' who wanted to see if an idea could work. It did.